{"title":"喀拉拉邦Kozhikode地区三级医疗机构COPD患者代谢综合征患病率","authors":"Noufal Chooriath, K. Narayan, P. Anandan","doi":"10.18410/jebmh/2021/611","DOIUrl":null,"url":null,"abstract":"BACKGROUND Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterised by progressive dyspnoea on exertion and cough. COPD is associated with comorbidities that influence mortality and hospitalizations independently. Metabolic syndrome (MS) consists of central obesity, hypertriglyceridemia, low levels of high-density lipoprotein (HDL), hyperglycaemia and hypertension. Presence of metabolic syndrome in patients with COPD increases the frequency of exacerbations and their duration. This study was done to find out prevalence of metabolic syndrome in COPD patients and its influence on exacerbations. METHODS This prospective observational study was conducted in a tertiary care teaching hospital in South India. 174 patients meeting the inclusion criteria were recruited for this prospective observational study, out of which 13 were excluded due to various reasons. Selected patients underwent detailed clinical examination and investigations including chest X-ray, spirometry, fasting blood sugar, fasting lipid profile, electrocardiogram (ECG) etc. Patients were further grouped in to those with metabolic syndrome and those without. They were followed up for one year with review on every two months for assessing exacerbation of COPD. Data was evaluated at the end of the study, statistical evaluation was done using Statistical Package for Social Sciences (SPSS software version18). RESULTS A total of 174 patients were recruited for the study, among which 13 were excluded. 161 patients were included in the final evaluation, out of which 157 patients were male (97.5 %). 44.7 % were belonging to global initiative for obstructive lung disease (GOLD stage III), 37.3 % stage IV and 18 % stage II. 70 (43.5 %) had metabolic syndrome. 51.6 % had normal body mass index (BMI), 23.6 % over weight and 3.7 % were obese. Mean number of exacerbations were 3.20 in those with metabolic syndrome, whereas 1.52 in those without, during the follow up period. CONCLUSIONS Prevalence of metabolic syndrome among COPD patients was 43.5 % in this study. COPD patients with metabolic syndrome had more mean number of exacerbations than those without metabolic syndrome. KEYWORDS COPD, Exacerbations, Metabolic Syndrome, Co-morbidities","PeriodicalId":15779,"journal":{"name":"Journal of Evidence Based Medicine and Healthcare","volume":"21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence of Metabolic Syndrome in COPD Patients Attending a Tertiary Care Setting, at Kozhikode District in Kerala\",\"authors\":\"Noufal Chooriath, K. Narayan, P. Anandan\",\"doi\":\"10.18410/jebmh/2021/611\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterised by progressive dyspnoea on exertion and cough. COPD is associated with comorbidities that influence mortality and hospitalizations independently. Metabolic syndrome (MS) consists of central obesity, hypertriglyceridemia, low levels of high-density lipoprotein (HDL), hyperglycaemia and hypertension. Presence of metabolic syndrome in patients with COPD increases the frequency of exacerbations and their duration. This study was done to find out prevalence of metabolic syndrome in COPD patients and its influence on exacerbations. METHODS This prospective observational study was conducted in a tertiary care teaching hospital in South India. 174 patients meeting the inclusion criteria were recruited for this prospective observational study, out of which 13 were excluded due to various reasons. Selected patients underwent detailed clinical examination and investigations including chest X-ray, spirometry, fasting blood sugar, fasting lipid profile, electrocardiogram (ECG) etc. Patients were further grouped in to those with metabolic syndrome and those without. They were followed up for one year with review on every two months for assessing exacerbation of COPD. Data was evaluated at the end of the study, statistical evaluation was done using Statistical Package for Social Sciences (SPSS software version18). RESULTS A total of 174 patients were recruited for the study, among which 13 were excluded. 161 patients were included in the final evaluation, out of which 157 patients were male (97.5 %). 44.7 % were belonging to global initiative for obstructive lung disease (GOLD stage III), 37.3 % stage IV and 18 % stage II. 70 (43.5 %) had metabolic syndrome. 51.6 % had normal body mass index (BMI), 23.6 % over weight and 3.7 % were obese. Mean number of exacerbations were 3.20 in those with metabolic syndrome, whereas 1.52 in those without, during the follow up period. CONCLUSIONS Prevalence of metabolic syndrome among COPD patients was 43.5 % in this study. COPD patients with metabolic syndrome had more mean number of exacerbations than those without metabolic syndrome. KEYWORDS COPD, Exacerbations, Metabolic Syndrome, Co-morbidities\",\"PeriodicalId\":15779,\"journal\":{\"name\":\"Journal of Evidence Based Medicine and Healthcare\",\"volume\":\"21 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Evidence Based Medicine and Healthcare\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18410/jebmh/2021/611\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Evidence Based Medicine and Healthcare","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18410/jebmh/2021/611","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Prevalence of Metabolic Syndrome in COPD Patients Attending a Tertiary Care Setting, at Kozhikode District in Kerala
BACKGROUND Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterised by progressive dyspnoea on exertion and cough. COPD is associated with comorbidities that influence mortality and hospitalizations independently. Metabolic syndrome (MS) consists of central obesity, hypertriglyceridemia, low levels of high-density lipoprotein (HDL), hyperglycaemia and hypertension. Presence of metabolic syndrome in patients with COPD increases the frequency of exacerbations and their duration. This study was done to find out prevalence of metabolic syndrome in COPD patients and its influence on exacerbations. METHODS This prospective observational study was conducted in a tertiary care teaching hospital in South India. 174 patients meeting the inclusion criteria were recruited for this prospective observational study, out of which 13 were excluded due to various reasons. Selected patients underwent detailed clinical examination and investigations including chest X-ray, spirometry, fasting blood sugar, fasting lipid profile, electrocardiogram (ECG) etc. Patients were further grouped in to those with metabolic syndrome and those without. They were followed up for one year with review on every two months for assessing exacerbation of COPD. Data was evaluated at the end of the study, statistical evaluation was done using Statistical Package for Social Sciences (SPSS software version18). RESULTS A total of 174 patients were recruited for the study, among which 13 were excluded. 161 patients were included in the final evaluation, out of which 157 patients were male (97.5 %). 44.7 % were belonging to global initiative for obstructive lung disease (GOLD stage III), 37.3 % stage IV and 18 % stage II. 70 (43.5 %) had metabolic syndrome. 51.6 % had normal body mass index (BMI), 23.6 % over weight and 3.7 % were obese. Mean number of exacerbations were 3.20 in those with metabolic syndrome, whereas 1.52 in those without, during the follow up period. CONCLUSIONS Prevalence of metabolic syndrome among COPD patients was 43.5 % in this study. COPD patients with metabolic syndrome had more mean number of exacerbations than those without metabolic syndrome. KEYWORDS COPD, Exacerbations, Metabolic Syndrome, Co-morbidities